A Boston-based team and a group led by Roche's Genentech unit have each identified new kinase regulators of WNT signaling-YES1 and RIPK4, respectively-that provide two new, druggable targets. Each team will now look for the cancer subtypes most likely to respond to inhibitors of these kinases.